EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD. Duravyu failed to show it was ‘non-inferior’ compared to the standard treatment for wet AMD. In contrast, Ocular’s SOL-1 Phase 3 trial met its primary endpoint for Wet AMD in February. Despite … Read more